{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T14:24:13Z","timestamp":1788272653770,"version":"build-2803163510"},"reference-count":55,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100017160","name":"Beni-Suef University","doi-asserted-by":"publisher","award":["YR4-BSU2114"],"award-info":[{"award-number":["YR4-BSU2114"]}],"id":[{"id":"10.13039\/100017160","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Bioorganic Chemistry"],"published-print":{"date-parts":[[2025,6]]},"DOI":"10.1016\/j.bioorg.2025.108429","type":"journal-article","created":{"date-parts":[[2025,4,5]],"date-time":"2025-04-05T16:29:42Z","timestamp":1743870582000},"page":"108429","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":5,"special_numbering":"C","title":["Synthesis of new selective agents with dual anti-inflammatory and SARS-CoV-2 Mpro inhibitory activity: Antipyrine-celecoxib hybrid analogues; COX-2, COVID-19 cytokine storm and replication inhibitory activities."],"prefix":"10.1016","volume":"160","author":[{"given":"Eman K.A.","family":"Abdelall","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Heba A.H.","family":"Elshemy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Madlen B.","family":"Labib","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John N.","family":"Philoppes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fares E.M.","family":"Ali","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amira K.M.","family":"Ahmed","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.bioorg.2025.108429_bb0005","doi-asserted-by":"crossref","DOI":"10.1016\/j.molstruc.2021.130554","article-title":"Design, synthesis of new anti-inflammatory agents with a pyrazole core\u00a0: COX-1 \/ COX-2 inhibition assays, anti-inflammatory, ulcerogenic, histopathological, molecular modeling, and ADME studies","volume":"1240","author":"Abdellatif","year":"2021","journal-title":"J. Mol. Struct."},{"key":"10.1016\/j.bioorg.2025.108429_bb0010","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1016\/j.bioorg.2018.03.011","article-title":"Design, synthesis of novel isoindoline hybrids as COX-2 inhibitors: anti-inflammatory, analgesic activities and docking study","volume":"78","author":"Labib","year":"2018","journal-title":"Bioorg. Chem."},{"key":"10.1016\/j.bioorg.2025.108429_bb0015","doi-asserted-by":"crossref","first-page":"644","DOI":"10.1038\/384644a0","article-title":"Structural basis for selective inhibition of cyclooxygenase-2 by anti-inflammatory agents","volume":"384","author":"Kurumbail","year":"1996","journal-title":"Nature"},{"key":"10.1016\/j.bioorg.2025.108429_bb0020","doi-asserted-by":"crossref","DOI":"10.1016\/j.bioorg.2021.105122","article-title":"Optimization of pyrazole-based compounds with 1,2,4-triazole-3-thiol moiety as selective COX-2 inhibitors cardioprotective drug candidates: design, synthesis, cyclooxygenase inhibition, anti-inflammatory, ulcerogenicity, cardiovascular evaluation, and Mol","volume":"114","author":"Abdellatif","year":"2021","journal-title":"Bioorg. Chem."},{"key":"10.1016\/j.bioorg.2025.108429_bb0025","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1080\/14756366.2022.2145283","article-title":"Novel N -methylsulfonyl-indole derivatives: biological activity and COX-2\/5-LOX inhibitory effect with improved gastro protective profile and reduced cardio vascular risks","volume":"38","author":"Philoppes","year":"2023","journal-title":"J. Enzyme Inhib. Med. Chem."},{"key":"10.1016\/j.bioorg.2025.108429_bb0030","doi-asserted-by":"crossref","DOI":"10.1016\/j.bioorg.2021.105302","article-title":"Novel 1,5-diaryl pyrazole-3-carboxamides as selective COX-2\/sEH inhibitors with analgesic, anti-inflammatory, and lower cardiotoxicity effects","volume":"116","author":"Hendawy","year":"2021","journal-title":"Bioorg. Chem."},{"key":"10.1016\/j.bioorg.2025.108429_bb0035","doi-asserted-by":"crossref","DOI":"10.1016\/j.bioorg.2020.104308","article-title":"Novel tetrazole-based selective COX-2 inhibitors: design, synthesis, anti-inflammatory activity, evaluation of PGE2, TNF- \u03b1, IL-6 and histopathological study","volume":"104","author":"Labib","year":"2020","journal-title":"Bioorg. Chem."},{"key":"10.1016\/j.bioorg.2025.108429_bb0040","first-page":"831","article-title":"Inflammation in COVID-19\u00a0: from pathogenesis to treatment","volume":"14","author":"Wong","year":"2021","journal-title":"Int. J. Clin. Exp. Pathol."},{"key":"10.1016\/j.bioorg.2025.108429_bb0045","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1038\/d41573-020-00110-3","article-title":"Immune status could determine efficacy of COVID-19 therapies","volume":"19","author":"Cully","year":"2020","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.bioorg.2025.108429_bb0050","doi-asserted-by":"crossref","DOI":"10.1016\/j.bioorg.2022.106255","article-title":"Exploring the dual effect of novel 1,4-diarylpyranopyrazoles as antiviral and anti-inflammatory for the management of SARS-CoV-2 and associated inflammatory symptoms","volume":"130","author":"Malebari","year":"2023","journal-title":"Bioorg. Chem."},{"key":"10.1016\/j.bioorg.2025.108429_bb0055","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1159\/000518581","article-title":"The impact of the COVID-19 pandemic on dementia risk: potential pathways to cognitive decline","volume":"2","author":"Pyne","year":"2021","journal-title":"Neurodegener. Dis."},{"key":"10.1016\/j.bioorg.2025.108429_bb0060","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3389\/fimmu.2020.02167","volume":"11","author":"Verrall","year":"2020","journal-title":"Front. Immunol."},{"key":"10.1016\/j.bioorg.2025.108429_bb0065","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.03006-2020","article-title":"Confronting the controversy: Interleukin-6 and the COVID-19 cytokine storm syndrome","author":"Chen","year":"2020","journal-title":"Eur. Respir. J."},{"key":"10.1016\/j.bioorg.2025.108429_bb0070","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1684\/ecn.2020.0451","article-title":"Cytokine release syndrome\u00a0: inhibition of pro-inflammatory cytokines as a solution for reducing COVID-19 mortality cytokine release syndrome: inhibition of pro-inflammatory cytokines as a solution for reducing COVID-19 mortality","volume":"31","author":"Moradian","year":"2020","journal-title":"Eur. Cytokine Netw."},{"key":"10.1016\/j.bioorg.2025.108429_bb0075","doi-asserted-by":"crossref","DOI":"10.1016\/j.clim.2022.109022","article-title":"Anti-inflammatory and immune therapy in severe coronavirus disease 2019 (COVID-19) patients: an update","volume":"239","author":"Zhang","year":"2022","journal-title":"Clin. Immunol."},{"key":"10.1016\/j.bioorg.2025.108429_bb0080","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3389\/fphar.2020.561674","article-title":"Celebrex Adjuvant Therapy on Coronavirus Disease 2019: An Experimental Study","volume":"11","author":"Hong","year":"2020","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.bioorg.2025.108429_bb0085","doi-asserted-by":"crossref","first-page":"1645","DOI":"10.1007\/s10787-022-01029-4","article-title":"Short-term celecoxib (celebrex) adjuvant therapy: a clinical trial study on COVID-19 patients","volume":"30","author":"Ghaznavi","year":"2022","journal-title":"Inflammopharmacology"},{"key":"10.1016\/j.bioorg.2025.108429_bb0090","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/j.ijid.2020.09.1466","article-title":"COX2 inhibition in the treatment of COVID-19: review of literature to propose repositioning of celecoxib for randomized controlled studies","volume":"101","author":"Baghaki","year":"2020","journal-title":"Int. J. Infect. Dis."},{"key":"10.1016\/j.bioorg.2025.108429_bb0095","doi-asserted-by":"crossref","first-page":"177","DOI":"10.3390\/biomed3010015","article-title":"Early multi-target treatment of mild-to-moderate COVID-19, Particularly in Terms of Non-Steroidal Anti-Inflammatory Drugs and Indomethacin","volume":"3","author":"Fazio","year":"2023","journal-title":"BioMed"},{"key":"10.1016\/j.bioorg.2025.108429_bb0100","doi-asserted-by":"crossref","first-page":"3793","DOI":"10.3390\/ijms21113793","article-title":"Prediction of novel inhibitors of the Main protease (M-pro) of SARS-CoV-2 through consensus docking and drug reposition","volume":"21","author":"Gimeno","year":"2020","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.bioorg.2025.108429_bb0105","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2020.112702","article-title":"Potent inhibitors of SARS-CoV-2 3C-like protease derived from N-substituted isatin compounds","volume":"206","author":"Liu","year":"2020","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.bioorg.2025.108429_bb0110","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2023.115491","article-title":"The research progress of SARS-CoV-2 main protease inhibitors from 2020 to 2022","volume":"257","author":"Pang","year":"2023","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.bioorg.2025.108429_bb0115","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2020.112711","article-title":"The development of coronavirus 3C-like protease (3CL pro) inhibitors from 2010 to 2020","volume":"206","author":"Liu","year":"2020","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.bioorg.2025.108429_bb0120","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2023.115487","article-title":"Discovery of quinazolin-4-one-based non-covalent inhibitors targeting the severe acute respiratory syndrome coronavirus 2 main protease (SARS-CoV-2 M pro)","volume":"257","author":"Zhang","year":"2023","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.bioorg.2025.108429_bb0125","doi-asserted-by":"crossref","first-page":"2080","DOI":"10.1016\/j.bmc.2014.02.042","article-title":"Synthesis and biological evaluation of new pyrazolone \u2013 pyridazine conjugates as anti-inflammatory and analgesic agents","volume":"22","author":"Khalil","year":"2014","journal-title":"Bioorg. Med. Chem."},{"key":"10.1016\/j.bioorg.2025.108429_bb0130","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1016\/j.bioorg.2018.03.011","article-title":"Design, synthesis, analgesic, anti-inflammatory activity of novel pyrazolones possessing aminosulfonyl pharmacophore as inhibitors of COX-2\/5-LOX enzymes: histopathological and docking studies","volume":"78","author":"Abdelgawad","year":"2018","journal-title":"Bioorg. Chem."},{"key":"10.1016\/j.bioorg.2025.108429_bb0135","doi-asserted-by":"crossref","first-page":"2285","DOI":"10.1016\/j.bmcl.2005.03.007","article-title":"The development of monocyclic pyrazolone based cytokine synthesis inhibitors","volume":"15","author":"Golebiowski","year":"2005","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"10.1016\/j.bioorg.2025.108429_bb0140","doi-asserted-by":"crossref","first-page":"7849","DOI":"10.1016\/j.bmc.2010.09.050","article-title":"Synthesis and evaluation of pyrazolone compounds as SARS-coronavirus 3C-like protease inhibitors","volume":"18","author":"Ramajayam","year":"2010","journal-title":"Bioorg. Med. Chem."},{"key":"10.1016\/j.bioorg.2025.108429_bb0145","doi-asserted-by":"crossref","first-page":"3035","DOI":"10.1016\/j.bmc.2016.05.013","article-title":"Identification, synthesis and evaluation of SARS-CoV and MERS-CoV 3C-like protease inhibitors","volume":"24","author":"Kumar","year":"2016","journal-title":"Bioorg. Med. Chem."},{"key":"10.1016\/j.bioorg.2025.108429_bb0150","doi-asserted-by":"crossref","DOI":"10.3389\/fchem.2019.00214","article-title":"Design, synthesis, antiviral evaluation, and SAR studies of new 1-(Phenylsulfonyl)-1H-Pyrazol\u22124-yl- Methylaniline derivatives","volume":"7","author":"Desideri","year":"2019","journal-title":"Front. Chem."},{"key":"10.1016\/j.bioorg.2025.108429_bb0155","doi-asserted-by":"crossref","first-page":"8017","DOI":"10.1128\/JVI.00998-13","article-title":"Novel inhibitors of severe acute respiratory syndrome coronavirus entry that act by three distinct mechanisms","volume":"87","author":"Adedeji","year":"2013","journal-title":"J. Virol."},{"key":"10.1016\/j.bioorg.2025.108429_bb0160","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1016\/j.febslet.2008.12.059","article-title":"Individual and common inhibitors of coronavirus and picornavirus main proteases","volume":"583","author":"Kuo","year":"2009","journal-title":"FEBS Lett."},{"key":"10.1016\/j.bioorg.2025.108429_bb0165","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1016\/j.bioorg.2018.06.036","article-title":"Synthesis, biological evaluation and docking study of 1,3,4-thiadiazole-thiazolidinone hybrids as anti-inflammatory agents with dual inhibition of COX-2 and 15-LOX","volume":"80","author":"Omar","year":"2018","journal-title":"Bioorg. Chem."},{"key":"10.1016\/j.bioorg.2025.108429_bb0170","doi-asserted-by":"crossref","first-page":"E55","DOI":"10.1002\/jhet.1056","article-title":"Synthesis and anticancer and antiviral activities of new 2-Pyrazoline-substituted 4- Thiazolidinones","volume":"50","author":"Havrylyuk","year":"2013","journal-title":"J. Heterocyclic Chem."},{"key":"10.1016\/j.bioorg.2025.108429_bb0175","doi-asserted-by":"crossref","first-page":"3746","DOI":"10.1016\/j.ejmech.2009.03.038","article-title":"Synthesis and antiviral activity of new pyrazole and thiazole derivatives","volume":"44","author":"El-Sabbagh","year":"2009","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.bioorg.2025.108429_bb0180","doi-asserted-by":"crossref","first-page":"2632","DOI":"10.1007\/s00044-015-1327-7","article-title":"Synthesis, cyclooxygenase inhibition, and anti-inflammatory evaluation of novel diarylheterocycles with a central pyrazole, pyrazoline, or pyridine ring","volume":"24","author":"Abdellatif","year":"2015","journal-title":"Med. Chem. Res."},{"key":"10.1016\/j.bioorg.2025.108429_bb0185","doi-asserted-by":"crossref","first-page":"534","DOI":"10.1021\/jm301580n","volume":"56","author":"Jacobs","year":"2013","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.bioorg.2025.108429_bb0190","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1002\/ardp.19833160115","article-title":"Reactions with 3-Pyrazolin-5-ones: synthesis of some 4-substituted 2,3-dimethyl-l-phenyl-3-pyrazolin-5-ones","volume":"316","author":"El-Sakka","year":"1983","journal-title":"Arch. Pharm."},{"key":"10.1016\/j.bioorg.2025.108429_bb0195","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0240079","article-title":"Biochemical screening for SARS-CoV-2 main protease inhibtors","volume":"15","author":"Coelho","year":"2020","journal-title":"PLoS One"},{"key":"10.1016\/j.bioorg.2025.108429_bb0200","doi-asserted-by":"crossref","DOI":"10.1016\/j.bioorg.2021.104767","article-title":"Discovery of novel inhibitors against main protease (Mpro) of SARS-CoV-2 via virtual screening and biochemical evaluation","volume":"110","author":"Guo","year":"2021","journal-title":"Bioorg. Chem."},{"key":"10.1016\/j.bioorg.2025.108429_bb0205","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1002\/ardp.19552880812","article-title":"Uber die Darstellung von Ketonen der Antipyrinreihe mit Hilfe von Phosphoroxychlorid","volume":"288","author":"Klosa","year":"1955","journal-title":"Arch. Pharm."},{"key":"10.1016\/j.bioorg.2025.108429_bb0210","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/S0169-409X(00)00129-0","article-title":"Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings","volume":"46","author":"Lipinski","year":"2001","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.bioorg.2025.108429_bb0215","series-title":"Theory and Practice of Histological Techniques, (2008): Elsevier Health Sciences","author":"Bancroft","year":"2008"},{"key":"10.1016\/j.bioorg.2025.108429_bb0220","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/0014-2999(79)90144-4","article-title":"Cholinergic-mediated gastric mast cell degranulation with subsequent histamine H1-and H2-receptor activation in stress ulceration in rats","volume":"55","author":"Cho","year":"1979","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.bioorg.2025.108429_bb0225","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.bioorg.2015.11.001","article-title":"Design, synthesis and biological screening of new 4-thiazolidinone derivatives with promising COX-2 selectivity, anti-inflammatory activity and gastric safety profile","volume":"64","author":"Abdellatif","year":"2016","journal-title":"Bioorg. Chem."},{"key":"10.1016\/j.bioorg.2025.108429_bb0230","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1016\/0014-5793(71)80319-8","article-title":"Immunoassay using antigen\u2014enzyme conjugates","volume":"15","author":"Weemen","year":"1971","journal-title":"FEBS Lett."},{"key":"10.1016\/j.bioorg.2025.108429_bb0235","doi-asserted-by":"crossref","DOI":"10.1007\/s11010-023-04662-x","article-title":"Lansoprazole attenuates cyclophosphamide-induced cardiopulmonary injury by modulating redox-sensitive pathways and inflammation","author":"Hassanein","year":"2023","journal-title":"Mol. Cell. Biochem."},{"key":"10.1016\/j.bioorg.2025.108429_bb0240","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1080\/13880209.2019.1621353","article-title":"Fermented dried Citrus unshiu peel extracts exert anti-inflammatory activities in LPS-induced RAW264. 7 macrophages and improve skin moisturizing efficacy in immortalized human HaCaT keratinocytes","volume":"57","author":"Kim","year":"2019","journal-title":"Pharm. Biol."},{"key":"10.1016\/j.bioorg.2025.108429_bb0245","doi-asserted-by":"crossref","DOI":"10.1016\/j.bioorg.2021.104862","article-title":"Novel inhibitors of the main protease enzyme of SARS-CoV-2 identified via molecular dynamics simulation-guided in vitro assay","volume":"111","author":"Loschwitz","year":"2021","journal-title":"Bioorg. Chem."},{"key":"10.1016\/j.bioorg.2025.108429_bb0250","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2023.115186","article-title":"Novel dithiocarbamates selectively inhibit 3CL protease of SARS-CoV-2 and other coronaviruses","volume":"250","author":"Brier","year":"2023","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.bioorg.2025.108429_bb0255","series-title":"Cyclooxygenase-2 (Prostaglandin Synthase-2) Complexed with a Selective Inhibitor, SC-558","author":"Kurumbail","year":"1779"},{"key":"10.1016\/j.bioorg.2025.108429_bb0260","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1021\/acscentsci.1c00039","article-title":"Potent noncovalent inhibitors of the Main protease of SARS-CoV - 2 from molecular sculpting of the drug Perampanel guided by free energy perturbation calculations","volume":"7","author":"Zhang","year":"2021","journal-title":"ACS Cent. Sci."},{"key":"10.1016\/j.bioorg.2025.108429_bb0265","doi-asserted-by":"crossref","DOI":"10.1080\/14756366.2023.2234665","article-title":"Identification of sulphonamide \u2013tethered N-((triazole-4-yl)methyl)isatin derivatives as inhibitors of SARS-Cov-2 main protease","volume":"38","author":"ElNaggar","year":"2023","journal-title":"J. Enzyme Inhib. Med. Chem."},{"key":"10.1016\/j.bioorg.2025.108429_bb0270","doi-asserted-by":"crossref","first-page":"42717","DOI":"10.1038\/srep42717","article-title":"SwissADME: Afree web tool to evaluate pharmacokinetics, drug-likeness and medicinal chemistry friendliness of small molecules","volume":"7","author":"Daina","year":"2017","journal-title":"Sci. Rep."},{"key":"10.1016\/j.bioorg.2025.108429_bb0275","doi-asserted-by":"crossref","first-page":"4002","DOI":"10.3390\/molecules26134002","article-title":"In Silico Approach Using Free Software to Optimize the Antiproliferative Activity and Predict the Potential Mechanism of Action of Pyrrolizine-Based Schiff Bases","volume":"26","author":"Almalki","year":"2021","journal-title":"Molecules"}],"container-title":["Bioorganic Chemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0045206825003098?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0045206825003098?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,4,29]],"date-time":"2026-04-29T11:58:43Z","timestamp":1777463923000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0045206825003098"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6]]},"references-count":55,"alternative-id":["S0045206825003098"],"URL":"https:\/\/doi.org\/10.1016\/j.bioorg.2025.108429","relation":{},"ISSN":["0045-2068"],"issn-type":[{"value":"0045-2068","type":"print"}],"subject":[],"published":{"date-parts":[[2025,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Synthesis of new selective agents with dual anti-inflammatory and SARS-CoV-2 Mpro inhibitory activity: Antipyrine-celecoxib hybrid analogues; COX-2, COVID-19 cytokine storm and replication inhibitory activities.","name":"articletitle","label":"Article Title"},{"value":"Bioorganic Chemistry","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bioorg.2025.108429","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"108429"}}